The achievement of project “Pre-clinical and clinical development of DBPR112, a novel EGFR tyrosine kinase inhibitor as a therapeutic candidate for lung adenocarcinoma” had been awarded the 2022 National Innovation Award in the Renewal and Issue the Excelsior Award in the early Dec. of 2022, by the Research Center for Biotechnology and Medicine Policy.
